UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
EARLY_PHASE1
36
about 5.9 years
0.0833333333333333–30
1 site in TX
About this study
This trial is testing a treatment to see if it's safe and effective in replacing some chemotherapy cycles with other treatments for children newly diagnosed with acute myeloid leukemia (AML). The goal is to improve survival while reducing long-term side effects. Researchers will monitor participants for up to three years after enrollment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Intrathecal triple
- 2.SOC
- 3.Take Asparaginase Erwinia Chrysanthemi (recombinant)
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS, cytarabine, etoposide, fludarabine, Antineoplastic Agent [TC] (Topoisomerase 2 Inhibitors), venetoclax
injection (Injection), injection, intravenous, oral (Oral Capsule), oral
Primary: Tolerability rate of Ida-FLA, Tolerability rate of VIA for HR patients, Tolerability rate of VIA for IR patients
Secondary: 3 year event-free survival, 3 year overall survival, Complete remission rate, Tolerability rate of intensified regimen as a whole for HR patients, Tolerability rate of intensified regimen as a whole for IR patients
Oncology